Avalglucosidase alfa is indicated for:
Population group: both men and women, only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)
Avalglucosidase alfa is indicated for long-term enzyme replacement therapy for the treatment of patients with Pompe disease (acid α-glucosidase deficiency).
For this indication, competent medicine agencies globally authorize below treatments (click for details):